Previous close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 1.2500 |
Strike | 2.00 |
Expiry date | 2024-05-17 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 22 |
Explore the financial dynamics and strategic clinical advancements as ACXP progresses with its Phase III trials.
Q1 2024 Acurx Pharmaceuticals Inc Earnings Call
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced the successful outcome of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of ibezapolstat for the treatment of C. difficile Infection into Phase 3 studies based on the recently completed Phase 2 clinical trial results.